Avandia’s Fate May Hang On How Advisory Cmte. Weighs Meta-Analyses Vs. Other Data
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA notes “considerable concern” about cardiovascular signal, while GSK points to positive epidemiologic data in the run-up to the July 30 committee meeting on the diabetes drug.
You may also be interested in...
Trasylol Could Face Labeling Changes After Joint Advisory Panel
Long-term observational study showing CV-renal risk for Bayer’s Trasylol should be judged in light of potentially inappropriate comparator drugs, FDA says.
Trasylol Could Face Labeling Changes After Joint Advisory Panel
Long-term observational study showing CV-renal risk for Bayer’s Trasylol should be judged in light of potentially inappropriate comparator drugs, FDA says.
Avandia Revenues Sink Under Safety Attack
Sales of rosiglitazone were hit the hardest in the U.S., falling 31 percent, GSK reports days ahead of an FDA advisory committee meeting.